One of the largest series was reported by Magnuson et al., which compared 351 patients with EGFRm NSCLC BrM across 6 institutions who received upfront first-generation EGFR TKI alone, SRS with adjuvant TKI or WBRT with adjuvant TKI.38 The mOS for patients who received upfront SRS, WBRT, and TKI first was 46, 30, and 25 months, respectively (P < .001). This evidence concerns the gene EGFR and non-small cell lung carcinoma.